Known as the Tykerb Evaluation After Chemotherapy (TEACH), this study is also sponsored by the manufacturer. Dr.
这项被称为TEACH (Tykerb化疗后评估)的研究也是由生产商赞助的。
Tykerb works by depriving tumor cells of signals needed to grow. Tykerb enters the cell and blocks the function of the HER2 protein.
拉帕替尼能阻断肿瘤细胞生长的信号,进入细胞后能阻止HER2蛋白发挥作用。
The FDA approval of Tykerb was based on the results of a study involving approximately 400 breast cancer patients with advanced-stage HER2 disease.
FDA参照大约400例晚期her 2阳性的乳腺癌病例的研究结果的基础上,批准了拉帕替尼应用于临床。
应用推荐